Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.